{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T01:14:39Z","timestamp":1787015679873,"version":"build-2736575974"},"reference-count":31,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2014,11,1]],"date-time":"2014-11-01T00:00:00Z","timestamp":1414800000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,11,1]],"date-time":"2014-11-01T00:00:00Z","timestamp":1414800000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,11,6]],"date-time":"2022-11-06T00:00:00Z","timestamp":1667692800000},"content-version":"vor","delay-in-days":2927,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"name":"Blood Transfusion Center of the German Red Cross Baden-W\u00fcrttemberg-Hessen","award":["GRK-1172"],"award-info":[{"award-number":["GRK-1172"]}]},{"DOI":"10.13039\/501100003495","name":"Hessisches Ministerium f\u00fcr Wissenschaft und Kunst","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100003495","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["jthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2014,11]]},"DOI":"10.1111\/jth.12731","type":"journal-article","created":{"date-parts":[[2014,9,15]],"date-time":"2014-09-15T12:40:10Z","timestamp":1410784810000},"page":"1861-1873","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Next generation FIX muteins with FVIII\u2010independent activity for alternative treatment of hemophilia A"],"prefix":"10.1016","volume":"12","author":[{"given":"P.","family":"Quade\u2010Lyssy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Abriss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Milanov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Ungerer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"K\u00f6nigs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Seifried","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Sch\u00fcttrumpf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"S1","key":"10.1111\/jth.12731_bb0010","first-page":"005","article-title":"Hemophilia: genetics, diagnosis and treatment","volume":"18","author":"Jaynardharan","year":"2011","journal-title":"J Genet Syndr Gene Ther"},{"key":"10.1111\/jth.12731_bb0015","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1055\/s-0037-1615621","article-title":"Definitions in hemophilia. Recommendation of the scientific subcommittee on factor VIII and factor IX of the scientific and standardization committee of the International Society on Thrombosis and Haemostasis","volume":"85","author":"White","year":"2001","journal-title":"Thromb Haemost"},{"key":"10.1111\/jth.12731_bb0020","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1111\/j.1600-0609.2012.01750.x","article-title":"Lifelong prophylaxis in a large cohort of adult patients with severe haemophilia: a beneficial effect on orthopaedic outcome and quality of life","volume":"88","author":"Khawaji","year":"2012","journal-title":"Eur J Haematol"},{"key":"10.1111\/jth.12731_bb0025","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1046\/j.1538-7836.2004.00710.x","article-title":"The incidence of factor VIII and factor IX inhibitors in the hemophilia population of the UK and their effect on subsequent mortality, 1977\u201099","volume":"2","author":"Darby","year":"2004","journal-title":"J Thromb Haemost"},{"key":"10.1111\/jth.12731_bb0030","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1111\/j.1365-2125.2010.03899.x","article-title":"Inhibitors of propagation of coagulation (factors VIII, IX and XI): a review of current therapeutic practice","volume":"72","author":"Franchini","year":"2011","journal-title":"Br J Clin Pharmacol"},{"key":"10.1111\/jth.12731_bb0035","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.thromres.2009.11.027","article-title":"Recombinant coagulation factor VIIa\u2013from molecular to clinical aspects of a versatile haemostatic agent","volume":"125","author":"Persson","year":"2010","journal-title":"Thromb Res"},{"key":"10.1111\/jth.12731_bb0040","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1055\/s-0037-1613284","article-title":"Myocardial infarction occurring in a case of acquired haemophilia during the treatment course with recombinant activated factor VII","volume":"88","author":"Guillet","year":"2002","journal-title":"Thromb Haemost"},{"key":"10.1111\/jth.12731_bb0045","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1055\/s-0037-1614918","article-title":"Acute myocardial infarction following administration of recombinant activated factor VII (Novo Seven) in a patient with haemophilia A and inhibitor","volume":"82","author":"Peerlinck","year":"1999","journal-title":"Thromb Haemost"},{"key":"10.1111\/jth.12731_bb0050","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1182\/blood-2011-05-353672","article-title":"Engineered factor IX variants bypass FVIII and correct hemophilia A phenotype in mice","volume":"119","author":"Milanov","year":"2012","journal-title":"Blood"},{"key":"10.1111\/jth.12731_bb0055","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1111\/jth.12572","article-title":"Oral gene therapy for hemophilia B using chitosan\u2010formulated FIX mutants","volume":"12","author":"Quade\u2010Lyssy","year":"2014","journal-title":"J Thromb Haemost"},{"key":"10.1111\/jth.12731_bb0060","doi-asserted-by":"crossref","first-page":"2316","DOI":"10.1182\/blood-2004-08-2990","article-title":"Factor IX variants improve gene therapy efficacy for hemophilia B","volume":"105","author":"Schuettrumpf","year":"2005","journal-title":"Blood"},{"key":"10.1111\/jth.12731_bb0065","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1111\/j.1538-7836.2009.03560.x","article-title":"Factor IX mutants with enhanced catalytic activity","volume":"7","author":"Hartmann","year":"2009","journal-title":"J Thromb Haemost"},{"key":"10.1111\/jth.12731_bb0070","series-title":"Enzymes: A Practical Introduction to Strucutre, Mechanism, and Data Analysis","author":"Copeland","year":"2000"},{"key":"10.1111\/jth.12731_bb0075","first-page":"WMC003247","article-title":"Comparison of Thrombin Generation Assay (TGA) and Non\u2010Activated Partial Thromboplastin Time (NAPTT) for the assessment of enhanced procoagulant activity in immunoglobulin solutions","volume":"3","author":"Roemisch","year":"2012","journal-title":"Immunotherapy"},{"key":"10.1111\/jth.12731_bb0080","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1016\/j.str.2009.10.011","article-title":"Structural basis of the cofactor\u2010 and substrate\u2010assisted activation of human coagulation factor IXa","volume":"17","author":"Zogg","year":"2009","journal-title":"Structure"},{"key":"10.1111\/jth.12731_bb0085","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1515\/BC.2009.057","article-title":"Activation mechanisms of coagulation factor IX","volume":"390","author":"Zogg","year":"2009","journal-title":"Biol Chem"},{"key":"10.1111\/jth.12731_bb0090","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1042\/bj3390217","article-title":"Regions 301\u2010303 and 333\u2010339 in the catalytic domain of blood coagulation factor IX are factor VIII\u2010interactive sites involved in stimulation of enzyme activity","volume":"339","author":"Kolkman","year":"1999","journal-title":"Biochem J"},{"key":"10.1111\/jth.12731_bb0095","doi-asserted-by":"crossref","first-page":"6626","DOI":"10.1093\/emboj\/16.22.6626","article-title":"Converting blood coagulation factor IXa into factor Xa: dramatic increase in amidolytic activity identifies important active site determinants","volume":"16","author":"Hopfner","year":"1997","journal-title":"EMBO J"},{"key":"10.1111\/jth.12731_bb0100","doi-asserted-by":"crossref","first-page":"6324","DOI":"10.1021\/bi00076a004","article-title":"Mutations in the catalytic domain of factor IX that are related to the subclass hemophilia Bm","volume":"32","author":"Hamaguchi","year":"1993","journal-title":"Biochemistry"},{"key":"10.1111\/jth.12731_bb0105","doi-asserted-by":"crossref","first-page":"16227","DOI":"10.1074\/jbc.271.27.16227","article-title":"Identification of the phospholipid binding site in the vitamin K\u2010dependent blood coagulation protein factor IX","volume":"271","author":"Freedman","year":"1996","journal-title":"J Biol Chem"},{"key":"10.1111\/jth.12731_bb0110","doi-asserted-by":"crossref","first-page":"31297","DOI":"10.1074\/jbc.M302840200","article-title":"The Gla domain of factor IXa binds to factor VIIIa in the tenase complex","volume":"278","author":"Blostein","year":"2003","journal-title":"J Biol Chem"},{"key":"10.1111\/jth.12731_bb0115","doi-asserted-by":"crossref","first-page":"3379","DOI":"10.1074\/jbc.M804955200","article-title":"The factor VIIIa C2 domain (residues 2228\u20102240) interacts with the factor IXa Gla domain in the factor Xase complex","volume":"284","author":"Soeda","year":"2009","journal-title":"J Biol Chem"},{"key":"10.1111\/jth.12731_bb0120","doi-asserted-by":"crossref","first-page":"25393","DOI":"10.1074\/jbc.M105432200","article-title":"Identification of functionally important residues of the epidermal growth factor\u20102 domain of factor IX by alanine\u2010scanning mutagenesis. Residues Asn(89)\u2010Gly(93) are critical for binding factor VIIIa","volume":"277","author":"Chang","year":"2002","journal-title":"J Biol Chem"},{"key":"10.1111\/jth.12731_bb0125","doi-asserted-by":"crossref","first-page":"5734","DOI":"10.1074\/jbc.M107753200","article-title":"The factor IXa second epidermal growth factor (EGF2) domain mediates platelet binding and assembly of the factor X activating complex","volume":"277","author":"Wilkinson","year":"2002","journal-title":"J Biol Chem"},{"key":"10.1111\/jth.12731_bb0130","doi-asserted-by":"crossref","first-page":"5725","DOI":"10.1074\/jbc.M107027200","article-title":"Residues 88\u2010109 of factor IXa are important for assembly of the factor X activating complex","volume":"277","author":"Wilkinson","year":"2002","journal-title":"J Biol Chem"},{"key":"10.1111\/jth.12731_bb0135","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1111\/j.1365-2516.2009.02039.x","article-title":"Inhibitors in factor IX deficiency a report of the ISTH\u2010SSC international FIX inhibitor registry (1997\u20132006)","volume":"15","author":"Chitlur","year":"2009","journal-title":"Haemophilia"},{"key":"10.1111\/jth.12731_bb0140","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/0014-5793(90)80535-Q","article-title":"A semi\u2010empirical method for prediction of antigenic determinants on protein antigens","volume":"276","author":"Kolaskar","year":"1990","journal-title":"FEBS Lett"},{"key":"10.1111\/jth.12731_bb0145","doi-asserted-by":"crossref","first-page":"e1002829","DOI":"10.1371\/journal.pcbi.1002829","article-title":"Reliable B cell epitope predictions: impacts of method development and improved benchmarking","volume":"8","author":"Kringelum","year":"2012","journal-title":"PLoS Comput Biol"},{"key":"10.1111\/jth.12731_bb0150","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.1056\/NEJMoa1108046","article-title":"Adenovirus\u2010associated virus vector\u2010mediated gene transfer in hemophilia B","volume":"365","author":"Nathwani","year":"2011","journal-title":"N Engl J Med"},{"issue":"Suppl. 1","key":"10.1111\/jth.12731_bb0155","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1111\/jth.12270","article-title":"Future of coagulation factor replacement therapy","volume":"11","author":"Peyvandi","year":"2013","journal-title":"J Thromb Haemost"},{"key":"10.1111\/jth.12731_bb0160","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/S0969-2126(99)80125-7","article-title":"Coagulation factor IXa: the relaxed conformation of Tyr99 blocks substrate binding","volume":"7","author":"Hopfner","year":"1999","journal-title":"Structure"}],"container-title":["Journal of Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjth.12731","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjth.12731","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783622041095?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783622041095?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/jth.12731\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T03:10:02Z","timestamp":1761534602000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1538783622041095"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,11]]},"references-count":31,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2014,11]]}},"alternative-id":["S1538783622041095"],"URL":"https:\/\/doi.org\/10.1111\/jth.12731","relation":{},"ISSN":["1538-7836"],"issn-type":[{"value":"1538-7836","type":"print"}],"subject":[],"published":{"date-parts":[[2014,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Next generation FIX muteins with FVIII\u2010independent activity for alternative treatment of hemophilia A","name":"articletitle","label":"Article Title"},{"value":"Journal of Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1111\/jth.12731","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 International Society on Thrombosis and Haemostasis. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}